Indeed, although several studies show that visfatin levels are higher in obese patients with T2D compared to non-diabetic obese patients [86,87,88,89], they do not differ between obese subjects with newly diagnosed glucose metabolism disorders (impaired fasting glucose, impaired glucose tolerance, or T2D) and obese subjects without these abnormalities [90]. Here, NAMPT is linked to Impaired glucose tolerance.